
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Protagenic Therapeutics (PTIX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: PTIX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $4
1 Year Target Price $4
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.21M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.38 | 52 Weeks Range 2.35 - 15.54 | Updated Date 06/30/2025 |
52 Weeks Range 2.35 - 15.54 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1639690 | Price to Sales(TTM) - |
Enterprise Value -1639690 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.64 | Shares Outstanding 868414 | Shares Floating 491613 |
Shares Outstanding 868414 | Shares Floating 491613 | ||
Percent Insiders 11.21 | Percent Institutions 4.75 |
Analyst Ratings
Rating 1 | Target Price 4 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Protagenic Therapeutics

Company Overview
History and Background
As of October 26, 2023, Protagenic Therapeutics appears to be a fictitious company or a company with very limited public information available. Therefore, a detailed history, founding year, and milestones cannot be provided. This analysis will be based on a hypothetical company profile.
Core Business Areas
- Drug Discovery: Focuses on identifying and developing novel therapeutic peptides for neurological disorders.
- Preclinical Development: Conducts in vitro and in vivo studies to assess the safety and efficacy of drug candidates.
- Licensing and Partnerships: Seeks strategic collaborations with pharmaceutical companies to advance clinical development and commercialization.
Leadership and Structure
Hypothetically, the company has a CEO with a background in pharmaceutical development and a scientific advisory board composed of leading neurologists and peptide chemists. It has a functional organizational structure with departments for research, preclinical development, and business development.
Top Products and Market Share
Key Offerings
- PT-101 (Hypothetical): A novel therapeutic peptide in preclinical development for the treatment of Alzheimer's disease. No market share data exists. Potential competitors include Biogen (BIIB), Eli Lilly (LLY), and Roche (ROG.SW) based on their Alzheimer's drug development programs.
- PT-202 (Hypothetical): A pre-clinical candidate for anxiety disorders. No market share data is available. Competitors include pharmaceutical companies marketing SSRIs and other anxiety medications, such as Pfizer (PFE) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in neurological disorders, is characterized by high unmet needs, lengthy development timelines, and significant regulatory hurdles. The Alzheimer's disease market is a large and growing market due to the aging population.
Positioning
Hypothetically, Protagenic Therapeutics is positioned as an innovative biotechnology company focused on developing peptide-based therapeutics for neurological diseases, targeting specific disease mechanisms. Its competitive advantage would be its novel peptide technology.
Total Addressable Market (TAM)
The Alzheimer's disease market is estimated at tens of billions of dollars annually. Protagenic Therapeutics, being in pre-clinical development, is targeting a portion of this TAM through licensing agreements or direct commercialization if PT-101 reaches the market.
Upturn SWOT Analysis
Strengths
- Novel peptide technology
- Experienced leadership team (hypothetical)
- Strong scientific advisory board (hypothetical)
- Focus on unmet medical needs
Weaknesses
- Preclinical stage of development
- Limited financial resources
- High risk of drug development failure
- Dependence on partnerships for clinical development
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
- Government funding for research and development
Threats
- Failure of drug candidates in clinical trials
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- PFE
- JNJ
- ROG.SW
Competitive Landscape
Protagenic Therapeutics faces significant competition from established pharmaceutical companies with greater resources and established pipelines. Its success depends on the differentiation and efficacy of its peptide therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Not Applicable
Future Projections: Future growth is highly dependent on the success of preclinical and clinical development programs and securing partnerships.
Recent Initiatives: Hypothetically, recent initiatives could include securing seed funding, initiating preclinical studies, and engaging with potential pharmaceutical partners.
Summary
Protagenic Therapeutics, being hypothetical, would be considered a high-risk, high-reward early-stage biotechnology company. Its peptide technology presents potential but needs to clear significant hurdles to reach the market. Securing partnerships and achieving positive preclinical and clinical results are critical for its survival and growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and publicly available information on similar biotechnology companies.
Disclaimers:
This analysis is based on a hypothetical company and should not be considered investment advice. Actual financial performance and market conditions may differ significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-01-05 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.